Study Suggests Alimta Drug Extends Life for Lung Cancer Patients

by: cancercompass

Eli Lilly and Co's drug Alimta is helping advanced lung cancer patients manage their disease for longer lives, reports Reuters.

At the recent American Society of Clinical Oncology meeting, doctors discussed research confirming Alimta's benefit for the nonsquamous type of non-small cell lung cancer.  The findings of this research specifically suggest patients with this type of lung cancer lived five months longer using Alimta than those randomly assigned a placebo.

Common side effects were fatigue and low white blood cell counts. There were no drug-related deaths in the study. According to Reuters, Alimta "is approved for use in combination with chemotherapy as an initial treatment for advanced nonsquamous non-small cell lung cancer."

Talk with advanced lung cancer patients about this and other therapies by joining the conversation at our Lung Cancer Message Board.